Panacea Biotec Reports Rs 1,214 Lakh Standalone Net Profit for Half-Year Ended September 2026
Total standalone income from operations reaches Rs 26,140 lakh; consolidated net profit for the period stands at Rs 1,411 lakh
Panacea Biotec Limited announced unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a standalone net profit of Rs 1,214 lakh for the half-year period, with total standalone income from operations at Rs 26,140 lakh. Consolidated net profit stood at Rs 1,411 lakh for the half-year. These results were reviewed and approved by the Audit Committee and Board on November 14, 2026.
Panacea Biotec Limited
Financial Results
Panacea Biotec Limited released its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, reporting a standalone net profit of Rs 1,214 lakh for the half-year period. The results were reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2026.
For the half-year ended September 30, 2026, Panacea Biotec’s standalone total income from operations was Rs 26,140 lakh, up from Rs 20,306 lakh in the same period last year.
The standalone net profit after tax for the half-year was Rs 1,214 lakh, compared to a loss of Rs 2,234 lakh in the previous year’s corresponding period.
On a consolidated basis, total income from operations for the half-year was Rs 38,924 lakh, with net profit after tax at Rs 1,411 lakh, improving from a Rs 1,005 lakh loss in the prior year.
The company’s earnings per equity share were Rs 1.98 (annualized basic and diluted) for the half-year standalone results.
These financial results have been subjected to limited review by the statutory auditors and are prepared in accordance with Indian Accounting Standards (Ind AS).
Highlights
- Standalone total income from operations: Rs 26,140 lakh for H1 FY2026-27.
- Standalone net profit after tax: Rs 1,214 lakh for H1 FY2026-27 versus loss of Rs 2,234 lakh previous year.
- Consolidated net profit after tax: Rs 1,411 lakh for H1 FY2026-27.
- Earnings per equity share (annualized): Rs 1.98 standalone.
- Financials audited and approved on November 14, 2026.
Key Data Snapshot
What happened
- Panacea Biotec Limited announced its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026.
- The financial results were reviewed by the Audit Committee and approved by the Board on November 14, 2026.
- The results have been subjected to limited review by the statutory auditors.
Financial performance
- Standalone total income from operations for the half-year was Rs 26,140 lakh, up from Rs 20,306 lakh in the previous year.
- Standalone net profit after tax was Rs 1,214 lakh for the half-year compared to a loss of Rs 2,234 lakh in the same period last year.
- Consolidated net profit after tax for the half-year stood at Rs 1,411 lakh, improved from a loss of Rs 1,005 lakh in the previous year.
- Earnings per equity share (annualized, standalone) were Rs 1.98.
Regulatory and governance context
- The results were prepared as per Indian Accounting Standards (Ind AS) notified under the Companies Act, 2013.
- These financials comply with SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.
- Results were published on the company’s website and stock exchange portals as per regulations.
Highlights
- Standalone total income from operations: Rs 26,140 lakh for H1 FY2026-27.
- Standalone net profit after tax: Rs 1,214 lakh for H1 FY2026-27 versus loss of Rs 2,234 lakh previous year.
- Consolidated net profit after tax: Rs 1,411 lakh for H1 FY2026-27.
- Earnings per equity share (annualized): Rs 1.98 standalone.
- Financials audited and approved on November 14, 2026.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Companies Act, 2013
- Indian Accounting Standards (Ind AS)
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Balaji Telefilms Announces Unaudited Q2 and H1 Financial Results for September 30, 2026
Balaji Telefilms Limited has released its unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2026. The results were reviewed by the company's independent auditor Deloitte Haskins & Sells LLP and include financial data from its subsidiaries Balaji Motion Pictures Limited and Ding Infinity Private Limited.
Read Full StoryGenesys International Announces Q2 FY2027 Unaudited Financials and Grants 3.65 Lakh Employee Stock Options at Discounted Prices
Genesys International Corporation Limited disclosed its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026, reporting a profit before tax of Rs.727.84 lakh in the quarter. The company also approved the grant of 3,65,000 employee stock options under its 2022 ESOP scheme, with exercise prices between Rs.70 to Rs.100, discounted significantly from the previous day's NSE closing price.
Read Full StoryShri Ram Apartment Development Co Ltd Submits Incomplete Filing with No Financial or Corporate Data
Shri Ram Apartment Development Co Ltd submitted a filing to BSE that only references annexures but does not contain any financial, corporate, or transactional information.
Read Full Story